Pulsenmore Ltd. (PLSM): Financial results for H1 2026
Pulsenmore Ltd. (PLSM) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026 Management to Host Webcast today at 8:30 am ET to discuss Results and Provide Business Update Omer, Israel –August 31, 2026 – Pulsenmore Ltd. (Nasdaq/TASE: PLSM ), a leadin
How this was made
The 30-second read
Why it matters
The earnings release provides fresh revenue and profit figures, plus details on a $7.5 M capital raise, offering traders new data to reassess valuation.
Market read
Primary earnings disclosure for a micro‑cap with modest growth and a capital raise; limited but actionable for niche investors.
What to watch
Future FDA approvals, manufacturing scale‑up costs, and reliance on a few key customers could materially affect performance.
Background
Pulsenmore Ltd. (Nasdaq/TASE: PLSM) is a remote maternal‑fetal healthcare company reporting its first half 2026 results and a private placement raise.
Ticker impact
Pulsenmore Ltd. filed its H1 2026 earnings release on Form 6‑K, disclosing revenue of $2 M, a 53% increase YoY and a private placement raise of $7.5 M.
Limited short‑term move; price may edge higher on the capital raise and FDA clearance news.
Numbers are small and already priced in for a niche medical‑device company; the primary catalyst is the earnings release itself.
Market effects
Highlights growing remote maternal‑fetal care market and potential demand for home ultrasound devices.
May boost Israeli med‑tech exposure and U.S. investors' interest in remote health solutions.
Limited; relevance confined to niche medical‑device and tele‑health sectors.
Counterpoint
Given the small scale and high operating losses, the stock may remain pressured despite the earnings beat.
Key entities
- CompanyPulsenmore Ltd.
Remote maternal‑fetal health device maker listed on Nasdaq/TASE.
- CustomerClalit Health Services
Major Israeli health insurer purchasing Pulsenmore devices.
